文献速递鼻科

慢性鼻窦炎伴鼻息肉生物制剂临床试验差异:是否在比较苹果与橘子?

Differences in Biologic Clinical Trials for Chronic Rhinosinusitis With Nasal Polyps-Are We Comparing Apples With Oranges?
PubMed 文献 · Int Forum Allergy Rhinol · 2026-07-03

本文聚焦慢性鼻窦炎伴鼻息肉(CRSwNP)生物制剂III期随机对照试验(RCT)间的差异,指出患者人群、试验设计、终点、地理、时机及数据处理等不同可影响结局,导致间接比较与荟萃分析难以恰当校正这些差异。

要点

  • CRSwNP生物制剂RCT在人群、设计、终点、地理、时机及数据处理上存在差异。
  • 这些差异可影响试验结局,间接比较与荟萃分析常未恰当校正。
  • 比较不同III期RCT结果时需警惕因研究间差异带来的挑战。

核心结论

  • 不同III期RCT间的差异可影响结局,直接比较或荟萃分析需谨慎解读。

研究设计与样本

  • 本文为综述,总结CRSwNP生物制剂III期RCT间可能影响结局的关键差异。

主要发现

  • RCT在患者人群、试验设计、终点、地理、时机或数据处理过程上存在差异。
  • 间接治疗比较与荟萃分析常未能恰当校正上述研究间差异。

临床怎么用

  • 解读CRSwNP生物制剂RCT疗效比较时,应关注研究间人群、设计、终点等差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In recent years, several biologics targeting Type 2 inflammation have been developed for treating chronic rhinosinusitis with nasal polyps (CRSwNP). These have been studied in registrational randomized controlled trials (RCTs), which vary in their patient populations, trial design, endpoints, geography, timing, or data-handling processes. While (in)direct treatment comparisons and meta-analyses have been carried out to compare efficacy results from RCTs, often these fail to properly account for these between-study differences. Here, we summarize the key between-study differences that can influence trial outcomes and highlight the resulting challenges faced when comparing outcomes from different Phase III RCTs of biologics in CRSwNP.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Cornet M, Hellings PW, Desrosiers M, et al. Differences in Biologic Clinical Trials for Chronic Rhinosinusitis With Nasal Polyps-Are We Comparing Apples With Oranges? Int Forum Allergy Rhinol. 2026. PMID: 42396965. doi:10.1002/alr.70205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。